A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
05/2011
05/19/2011	CA2781041A1 Spiropiperidine compounds as orl-1 receptor antagonists
05/19/2011	CA2780940A1 Crystalline forms of neurotrophin mimetic compounds and their salts
05/19/2011	CA2780568A1 Oxazoline derivatives for treatment of cns disorders
05/19/2011	CA2780541A1 Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells
05/19/2011	CA2780433A1 Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
05/19/2011	CA2780319A1 A method of promoting dendritic spine density
05/19/2011	CA2779508A1 Method and compositions for treating disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine d2l receptor
05/19/2011	CA2779290A1 Ligand-targeted multi-stereoisomer peptide polymer conjugates and uses thereof
05/19/2011	CA2778175A1 8-azabicyclo[3.2.1]octane-8-carboxamide derivative
05/19/2011	CA2772174A1 Xenon-based inhalable drug for treating or preventing induced dyskinesia
05/18/2011	EP2322642A2 Arachidonic acid and methods for the production and use thereof
05/18/2011	EP2322641A2 Arachidonic acid and methods for the production and use thereof
05/18/2011	EP2322640A2 Arachidonic acid and methods for the production and use thereof
05/18/2011	EP2322601A1 Method of collecting placental stem cells
05/18/2011	EP2322551A2 Compositions comprising Anti-IGF-1R Antibodies and Methods for their Production
05/18/2011	EP2322550A1 Compositions comprising anti-IGF-1R Antibodies and Methods for obtaining said Antibodies
05/18/2011	EP2322545A1 Analogues of GLP-1
05/18/2011	EP2322521A1 Heteroaryl compounds useful as inhibitors of GSK-3
05/18/2011	EP2322520A1 Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia
05/18/2011	EP2322517A1 Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
05/18/2011	EP2322506A1 Histamine H3 receptor agents, preparation and therapeutic uses
05/18/2011	EP2322501A1 4-dedimethylamino tetracycline compounds
05/18/2011	EP2322226A2 Solutions and methods for inhibition of pain, inflammation and cartilage degradation
05/18/2011	EP2322225A1 Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatigue syndrome and pain
05/18/2011	EP2322223A1 Therapeutic agent for migraine
05/18/2011	EP2322218A1 Methods of modulating CD200 receptors
05/18/2011	EP2322210A1 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
05/18/2011	EP2322205A1 Polymer-conjugated glycosylated neublastin
05/18/2011	EP2322199A1 Growth differentiation factor receptors, and methods of using same
05/18/2011	EP2322187A2 Use of uridine in combination with choline for the treatment of memory disorders
05/18/2011	EP2322185A2 Polynucleotide therapy
05/18/2011	EP2322179A1 Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders
05/18/2011	EP2322174A2 Combined use of valsartan and calcium channel blockers for therapeutic purposes
05/18/2011	EP2322170A1 Minimizing adverse experience associated with oxybutynin therapy
05/18/2011	EP2322168A1 Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
05/18/2011	EP2322167A1 Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
05/18/2011	EP2322166A1 Methods and compositions for reduction of side effects of therapeutic treatments
05/18/2011	EP2322164A2 Carbonylamino derivatives useful for the treatment of inflammatory bowel disease
05/18/2011	EP2322163A1 New therapeutics approaches for treating alzheimer disease
05/18/2011	EP2322154A2 Methods for detecting and clearing cross beta structure comprising proteins with crossbeta structure binding compounds.
05/18/2011	EP2322149A1 Methods and compositions for the treatment of ischemia
05/18/2011	EP2322147A1 Use of microparticles containing genetically modified cells in the treatment of neurodegenerative diseases
05/18/2011	EP2321408A2 Mesenchymal stromal cell populations and methods of isolating and using same
05/18/2011	EP2321351A2 Antibodies to ccr2
05/18/2011	EP2321324A1 Crystalline forms of a pyridine derivative
05/18/2011	EP2321321A1 Triazolo [4, 5-d]pyramidine derivatives and their use as purine receptor antagonists
05/18/2011	EP2321320A1 Novel compounds and their uses in diagnosis
05/18/2011	EP2321316A1 Substituted pyrimidin-4-one derivatives
05/18/2011	EP2321315A2 Substituted alkyl pyrimidin-4-one derivatives
05/18/2011	EP2321314A2 Substituted pyrimidone derivatives
05/18/2011	EP2321313A1 Substituted pyrimido [2, 1-a]isoquinolin-4-one derivatives
05/18/2011	EP2321303A2 Compounds that modulate intracellular calcium
05/18/2011	EP2321295A2 4-(pyridin-4-yl)-1h-[1,3,5]triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases
05/18/2011	EP2321288A1 Oxazole derivatives useful as inhibitors of faah
05/18/2011	EP2321287A1 4,5-dihydro-oxazol-2-yl derivatives
05/18/2011	EP2321286A1 Substituted n-oxide pyrazine derivatives
05/18/2011	EP2321278A2 PYRIDINYL MODULATORS OF y-SECRETASE
05/18/2011	EP2321265A1 Inositol and trehalose derivatives and pharmaceutical compositions for treating neurodegenerative diseases comprising the same
05/18/2011	EP2321258A1 Polymorphic form of rasagiline mesylate
05/18/2011	EP2321011A1 Diaryl compounds and uses thereof
05/18/2011	EP2320939A1 Tissue kallikrein for the treatment of parkinson's disease
05/18/2011	EP2320938A2 Use of human hyaluronidases for axonal regrowth
05/18/2011	EP2320934A2 Methods of treating cognitive impairment
05/18/2011	EP2320927A2 Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction
05/18/2011	EP2320925A2 Complement antagonists and uses thereof
05/18/2011	EP2320922A2 Combination of extracts of various plants for improving the symptoms of dementia disorders
05/18/2011	EP2320898A2 Smoking cessation kit and method
05/18/2011	EP2320897A1 Compositions and methods of treating amyloid disease
05/18/2011	EP2320892A2 Combination products
05/18/2011	EP2320891A1 Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system
05/18/2011	EP2320879A2 Pharmaceutical composition comprising jasmonates
05/18/2011	EP2320731A1 Methods and compositions for sleep disorders and other disorders
05/18/2011	EP2129672B1 Azaadamantane ester and carbamate derivatives and methods of use thereof
05/18/2011	EP2101762B1 Novel 2 -imidazoles as ligands for trace amine associated receptors (taar)
05/18/2011	EP2076502B1 Substituted carboxamides as group i metabotropic receptor antagonists
05/18/2011	EP2040755B1 Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
05/18/2011	EP1686984B1 Use of c-(2-phenyl-cyclohexyl)-methylamine compounds for the treatment of anxiety disorders
05/18/2011	EP1667984B1 Gamma-secretase inhibitors
05/18/2011	EP1581221B1 Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
05/18/2011	EP1268096B9 Extrusion die
05/18/2011	CN1958788B Gene recombined virus of human neurenergen 3
05/18/2011	CN1720225B N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
05/18/2011	CN102066930A Method of bioassaying yokkansan
05/18/2011	CN102066402A Peptide derivative and composition for promoting tear secretion comprising the same
05/18/2011	CN102066398A Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
05/18/2011	CN102066397A Compounds including an anti-inflammatory pharmacore and methods of use
05/18/2011	CN102066385A New peptidomimetic compounds
05/18/2011	CN102066384A Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
05/18/2011	CN102066381A Nalmefene prodrugs
05/18/2011	CN102066380A Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
05/18/2011	CN102066376A Anhydrous crystal form of orvepitant maleate
05/18/2011	CN102066359A Novel heteroaryl carboxamide derivatives
05/18/2011	CN102066358A CGRP receptor antagonists
05/18/2011	CN102066357A Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71
05/18/2011	CN102066356A Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7
05/18/2011	CN102066345A Oxazolidine derivatives as NMDA antagonists
05/18/2011	CN102066343A Trisubstituted 1, 2, 4 -triazoiies as nicotinic acetylcholine receptor modulators
05/18/2011	CN102066322A Compound having NPY Y5 receptor antagonist activity
05/18/2011	CN102066321A Pyrrolidine derivatives as NK2 receptor antagonists
05/18/2011	CN102066320A Aryl ketone as MRI

1 ... 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 ... 1833